Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, noviembre 03
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Oruka Therapeutics Inc
ORKA
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$100.70
5.27
5.53%
Últ. Act.: Nov 3, 1:24 PM
Get Report
Panorámica general
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Dividendos
Comparar
Opciones
Informe de acciones
Oruka Therapeutics Financials
Oruka Therapeutics (ORKA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Oruka Therapeutics Q2 EPS $(0.55) Misses $(0.51) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.51) by 7.84 percent. This is a 19.57 percent decrease over losses of $(0.46) per share
Benzinga Newsdesk
PRO
Oruka Therapeutics Q1 EPS $(0.48) Beats $(0.55) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.55) by 12.73 percent. This is a 20 percent decrease over losses of $(0.40) per share from
Benzinga Newsdesk
PRO
Oruka Therapeutics Q4 EPS $(0.45) Beats $(0.64) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.64) by 29.47 percent. This is a 8.16 percent increase over losses of $(0.49) per share from
Benzinga Newsdesk
PRO
Oruka Therapeutics Q3 EPS $(0.55) Beats $(0.59) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.59) by 6.14 percent. This is a 62.33 percent increase over losses of $(1.46) per share from
Benzinga Newsdesk
Stock Market Today: Dow Jones, Nasdaq, Futures Gain As Government Enters 2nd Week Of Shutdown—Plug, Lithium Americas, UiPath In Focus (UPDATED)
Editor’s Note: The future prices of benchmark tracking ETFs were updated in the story. U.S. stock futures rose on Monday following Friday’s mixed moves. Futures of major benchmark indices were higher.
Rishabh Mishra
Constellation Brands, Aehr Test Systems And 3 Stocks To Watch Heading Into Monday
US stock futures up, focus on Constellation Brands, SkyWater Tech, Aehr Test Systems, Oruka Therapeutics and VCI Global earnings.
Avi Kapoor
